Get the Stockscreener App
0.361
3.29%
-0.0123
Pre-market:
.37
0.009
+2.49%
Ensysce Biosciences Inc stock is traded at $0.361, with a volume of 871.59K.
It is down -3.29% in the last 24 hours and up +38.10% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$0.3733
Open:
$0.3734
24h Volume:
871.59K
Relative Volume:
0.07
Market Cap:
$7.02M
Revenue:
$4.71M
Net Income/Loss:
$-11.79M
P/E Ratio:
-0.1078
EPS:
-3.3492
Net Cash Flow:
$-9.72M
1W Performance:
-4.14%
1M Performance:
+38.10%
6M Performance:
-7.96%
1Y Performance:
-82.39%
1-Day Range:
$0.3536
$0.3734
1-Week Range:
$0.3536
$0.4055
52-Week Range:
$0.23
$2.75
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.361 | 7.35M | 4.71M | -11.79M | -9.72M | -3.3492 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
Ensysce (ENSC) completes private raise with contingent proceeds - Stock Titan
Ensysce (ENSC) chair boosts stake, locks in votes on merger - Stock Titan
ENSC: Acquisition and financing position CY200 for CRPS advancement, extending cash runway to 2027 - TradingView
ENSC: Acquisition and financing position CY200 for Phase II CRPS trial and long-term pipeline growth - TradingView
Ensysce Biosciences director Gower buys $444,169 in company stock - Investing.com
Ensysce Biosciences Insider Bought Shares Worth $444,169, According to a Recent SEC Filing - marketscreener.com
Ensysce Biosciences (ENSC) director buys stock and converts debt - Stock Titan
Ensysce Biosciences earnings beat by $0.51, revenue fell short of estimates - Investing.com Canada
MSN Money - MSN
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
Ensysce Completes Cy Biopharma Acquisition Adding Lead CRPS Candidate - Minichart
Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com Australia
Ensysce Q2 EPS beats; completes Cy Biopharma acquisition for $38.6m - scanx.trade
Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal - Stock Titan
Ensysce Biosciences Q2 net loss widens on higher R&D costs - TradingView
ENSC: Acquisition and new funding extend cash runway, with clinical pipeline and losses both increasing - TradingView
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - FinancialContent
ENSC Q1 2026 Earnings: Narrower-than-Expected Loss Marks 30% Beat Amid Persistent Share Weakness - vinanet.vn
Cy Biopharma merges with Ensysce Biosciences - Startupticker.ch
Ensysce Biosciences (ENSC) officer reports 154.8M underlying common via preferred - Stock Titan
Ensysce Biosciences Acquires Cy Biopharma to Expand Pain Pipeline - sekbernews.id
Ensysce Biosciences Inc (NASDAQ: ENSC) Share Price, ENSC Stock News, ENSC Share Price & Updates - Kalkine
Orrick Advises Cy Biopharma on Acquisition by Ensysce Biosciences and up to $77 Million Private Financing - orrick.com
Ensysce Biosciences Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Form 8K Ensysce Biosciences Inc For: 6 August By Investing.com - Investing.com South Africa
Ensysce Biosciences (ENSC) Drifts Lower as Shares Test Support Near $0.49Last Point Resistance - vinanet.vn
Ensysce completes Cy Biopharma acquisition, raises $21.5 million By Investing.com - Investing.com Australia
Ensysce Biosciences Acquires Cy Biopharma in Deal Backed by Up to $77 Million Financing - citybiz
Thursday's session: most active stocks - ChartMill
Ensysce Biosciences completes acquisition of Cy Biopharma - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Ensysce expands into neuroplastogenic pain with USD 77m Cy Biopharma acquisition - AllSci
Ensysce Biosciences Surges After Cy Biopharma Acquisition and Large Financing Package - Quiver Quantitative
Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing - Yahoo Finance
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Ensysce completes Cy Biopharma acquisition, raises $21.5 million - Investing.com
Ensysce Acquires Cy Biopharma, Expands Pain Therapy Portfolio - TipRanks
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Ensysce Biosciences (ENSC) Dips 3.18% to $0.37, Nearing Critical Support ZoneNAAIM Exposure - vinanet.vn
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch - Barchart.com
Ensysce Biosciences (NASDAQ:ENSC) surges 48%, still faces 141% climb for Nasdaq $1 threshold - TechStock²
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why is Ensysce Biosciences stock surging today? By Investing.com - Investing.com Canada
Why is Ensysce Biosciences stock surging today? - Investing.com
12 Health Care Stocks Moving In Monday's After-Market SessionEnsysce Biosciences (NASDAQ:ENSC), TransC - Benzinga
Ensysce lands $5.3M grant, completing $15.1M NIDA opioid-safety award - Dealroom
ENSC Q1 2026 Earnings: EPS Beat of 30.16% Highlights Cost Discipline Amid Pre-Revenue PipelineQuarterly Earnings Report - vinanet.vn
Ensysce Biosciences Inc (ENSC) Institutional Confidence - TradingKey
Ensysce Biosciences (ENSC) Edges Higher as Shares Test Key Resistance at $0.27Motive Wave - Vinanet
Ensysce Biosciences Inc (ENSC) Cash Flow - TradingKey
ENSC|Ensysce Biosciences Inc|Price:0.255|Chg%:-0.006 - TradingKey
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):